Generated by AI
Lantern Pharma Inc. is a clinical-stage biotechnology company focused on oncology drug discovery and development. Lantern Pharma uses artificial intelligence, machine learning, and genomic data through its proprietary RADR platform to identify precision cancer therapies and match them with the patient groups most likely to benefit. Its current portfolio includes multiple lead drug candidates and an antibody-drug conjugate program spanning several cancer indications, including solid tumors, blood cancers, and rare oncology settings. The company’s work centers on accelerating the development of targeted cancer treatments and improving the efficiency of clinical research through data-driven drug design and patient selection. Lantern Pharma Inc. is based in Dallas, Texas, and operates at the intersection of biotechnology, computational biology, and precision medicine.
Website1920 McKinney Avenue
Dallas, TX, 75201
United States
The latest articles about LTRN.
DALLAS, November 10, 2026--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, and its wholly owned subsidiary Starlight Therapeutics today announced the publication of Phase 1a clinical data for LP-184 (zirdafulven) in patients with recurrent GBM. LP-184 is being developed as STAR-001 for central nervous system (CNS) cancers. The paper appears in the October 2026 issue of Cancer Research Communications, a peer-reviewed journal of the American Association f
Detailed price information for Lantern Pharma Inc (LTRN-Q) from The Globe and Mail including charting and trades.
Summary of Nov 18's posts. Generated by AI.
Summary of Mar 31's posts. Generated by AI.
Summary of Mar 30's posts. Generated by AI.
Investors talking about LTRN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.